Clinical Trials Logo

Clinical Trial Summary

This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of surufatinib alone or combined with Anti-PD-1 mAb in the treatment of advanced Hepatocellular Carcinoma


Clinical Trial Description

This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of surufatinib alone or combined with Anti-PD-1 mAb in the treatment of advanced Hepatocellular Carcinoma. Cohort A: patients with advanced hepatocellular carcinoma who had failed previous standard first-line therapy and could not tolerate or reject existing therapies.Treatment:surufatinib combined with Anti-PD-1 mAb Cohort B: patients with advanced pancreatic cancer who had previously failed standard sencond-line therapy, could not tolerate or reject existing therapies.Treatment:surufatinib alone. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05282433
Study type Interventional
Source Zhongnan Hospital
Contact Fuxiang Zhou, MD,PhD
Phone +86-027-67813155
Email fuxiang.zhou@whu.edu.cn
Status Recruiting
Phase Phase 2
Start date April 16, 2022
Completion date December 31, 2024